Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 22, 2019
The WHO Recognizes NOX Inhibitors as New Therapeutic Class and Approves Setanaxib for GKT831
ARCHAMPS, France, July 22, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX) a biopharmaceutical company and the leader in NOX therapies, today announced ...
July 22, 2019
Saniona selects highly promising preclinical candidate with broad potential in autoimmune disorders
Saniona AB (SANION.ST) today announces that it has selected a new development candidate, SAN903, for preclinical development, which can enter clinical Phase 1 in only ...
July 22, 2019
Compugen Second Quarter 2019 Conference Call Scheduled for Monday, August 5, 2019 at 8:30 AM ET
HOLON, ISRAEL, July 22, 2019 /PRNewswire/ -- Compugen Ltd.(NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today ...
July 22, 2019
MediWound Launches EscharEx® U.S. Clinical Development Program
YAVNE, Israel, July 22, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (the “Company”) (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in ...
July 22, 2019
VBL Therapeutics Announces Modiin Production Facility Received a GMP Compliance Certificate Following EU QP Audit
TEL AVIV, Israel, July 22, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
July 22, 2019
Salarius Pharmaceuticals Announces Closing of Strategic Merger with Flex Pharma
HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that ...
July 22, 2019
DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
CUPERTINO, Calif., July 22, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the ...
July 22, 2019
Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors
HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it ...
July 22, 2019
Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress
DUBLIN, July 22, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial ...
July 22, 2019
ASIT biotech Raises EUR 9.225 Million in a Private Placement of Convertible Notes
BRUSSELS, Belgium, July 22, 2019 (GLOBE NEWSWIRE) -- ASIT biotech (Euronext:ASIT - BE0974289218), a Belgian biopharmaceutical company specialized in allergy immunotherapy, today announces that it ...
July 17, 2019
First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance in the American Journal of Transplantation
NANTES, France, July 17, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announces a scientific publication in the American Journal of Transplantation(1). This ...
July 17, 2019
Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF
ARCHAMPS, France, July 17, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX) a biopharmaceutical company and the leader in NOX therapies, announced today that ...
July 17, 2019
Nicox: Second Quarter 2019 Business Update and Financial Highlights
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided Q2 2019 operational highlights, revenue and cash position for Nicox and its subsidiaries ...
July 17, 2019
Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN
HAIFA, Israel, July 17, 2019 (GLOBE NEWSWIRE) --  Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, announced that ...
July 17, 2019
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in ...
July 17, 2019
DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission
CUPERTINO, Calif., July 17, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged that the submission of ...
July 17, 2019
CorMedix Presents at FDA Public Meeting on the Limited Population Pathway for Antibacterial and Antifungal Drugs
BERKELEY HEIGHTS, N.J., July 17, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
July 17, 2019
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency
VANCOUVER, July 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN), a leader in the development of minimally invasive transcatheter mitral valve ...
July 16, 2019
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
HOLON, Israel, July 16, 2019 /PRNewswire/ -- Compugen Ltd.(CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United ...
July 16, 2019
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
SAN DIEGO and TORONTO, July 16, 2019 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting ...
Page 5 of 158